During the study, participants will receive either ultevursen injections or undergo a sham procedure (which mimics the injection but without actually inserting anything into the eye). The medication will be given as a solution that is injected directly into the eye through a procedure called intravitreal injection. Some participants will receive higher doses of the medication while others will receive lower doses.

The study will track changes in participants’ vision and eye structure using various tests that measure the health of the retina (the light-sensitive layer at the back of the eye). Researchers will particularly focus on measuring a specific layer of the retina called the ellipsoid zone, which is typically affected in people with this condition. They will also monitor participants’ vision in different lighting conditions and their ability to see details and colors.

The purpose of this study is to evaluate how effective and safe Ultevursen is for people with this specific type of Retinitis Pigmentosa. Participants in the study will receive either the Ultevursen treatment or a placebo, which is a procedure that mimics the treatment but does not contain the active medication. The study will last for two years, during which participants will receive regular injections of the treatment directly into the eye, a method known as intravitreal use. Throughout the study, participants will have their vision and eye health monitored to assess any changes or improvements.

The study aims to gather information on how Ultevursen affects the progression of Retinitis Pigmentosa over time. Researchers will look at various aspects of vision, such as changes in the retina’s sensitivity and visual acuity, which is the clarity or sharpness of vision. The study will also monitor any side effects or adverse reactions to the treatment. This research is important for understanding how to better treat Retinitis Pigmentosa and potentially improve the quality of life for those affected by this condition.

The treatment involves an adeno-associated viral vector, which is a modified virus that carries genetic material to help restore light sensitivity in the eye. The medication is administered through an intravitreal injection, which means it is injected directly into the eye. After the injection, patients use special light-stimulating equipment as part of the treatment.

The main goal of this study is to test different doses of the treatment to determine if it is safe and well-tolerated by patients. The study will monitor patients for one year after receiving the treatment to check for any side effects and evaluate how well the treatment works. During this time, various tests will be performed to measure changes in vision and eye structure.

The purpose of the study is to evaluate the safety and effectiveness of AGTC-501 in improving vision in participants with this condition. Participants will be divided into groups, with some receiving the treatment and others not receiving any treatment (untreated control group). The study will monitor changes in vision and eye health over time, using various tests to assess how well the treatment works. These tests include measuring the sensitivity of the retina to light and checking the structure of the eye.

The study will last for several years, with regular check-ups to track the progress of participants. The main goal is to see if AGTC-501 can improve vision and whether it is safe to use. Participants will be closely monitored for any side effects or changes in their condition. This research aims to provide new insights into treating X-linked retinitis pigmentosa and potentially offer a new option for those affected by this genetic eye disease.

For Choroideremia, the treatment used is called AAV2-REP1, which is a type of gene therapy designed to deliver a healthy copy of a gene called REP1 to the eye. This therapy aims to prevent further vision loss or restore some lost vision function. For X-Linked Retinitis Pigmentosa, the treatment is AAV8-RPGR, which targets a different gene known as RPGR to help maintain or improve vision. Both treatments are administered through an injection directly into the eye.

The purpose of this study is to monitor the long-term effects of these treatments on participants who have already received them. Participants will undergo regular check-ups to assess their vision and overall eye health. The study will compare the outcomes of those who received the gene therapy with those who did not, to better understand the benefits and any potential risks associated with these treatments.

The purpose of the study is to evaluate the safety and tolerability of this new treatment when it is injected under the retina, which is the light-sensitive layer at the back of the eye. Participants will receive the treatment through a procedure called subretinal administration. The study will also aim to find the best dose that balances benefits and risks. Throughout the study, participants will undergo various health checks, including eye exams and blood tests, to monitor their response to the treatment.

Participants in the study will be monitored over a period of time to assess any side effects and to determine how well the treatment works in improving or stabilizing vision. The study will help researchers understand if this gene therapy can be a safe and effective option for people with Usher Syndrome Type 1B Retinitis Pigmentosa.

Several other treatments are also being evaluated in the study for different conditions, but they are not the primary focus for this particular investigation. These include atropine, dexamethasone, neomycin, and indometacin, all formulated as eye drops or solutions for eye treatment. Additionally, phenylephrine hydrochloride and tropicamide are used in an ophthalmic insert form.

The main goal of the study is to determine whether the HORA-PDE6B therapy is safe for use in patients with retinitis pigmentosa due to specific genetic changes. This involves careful monitoring for any adverse effects post-treatment, alongside regular eye exams and other medical assessments to ensure the well-being of participants.

Participants in the study will receive the ISTEM-01 treatment and will be monitored for any side effects or changes in their eye health. The study will involve regular eye exams and tests to check the placement of the therapeutic patch and to observe any changes in the eye’s structure and function. These tests include Ocular Coherence Tomography (OCT) scans, which provide detailed images of the eye, and other assessments to measure visual acuity and eye pressure.

Throughout the study, researchers will also evaluate the functionality of the retina and the Retinal Pigment Epithelium cells using various methods. The goal is to determine if the treatment can help preserve or improve vision in patients with retinitis pigmentosa. The study will continue to follow participants for long-term effects and outcomes beyond the initial 56 weeks.

Participants in this study will receive the gene therapy treatment through a procedure called subretinal injection, where the solution is injected under the retina. The study will monitor the participants over an extended period to assess how well the treatment works and to ensure it is safe. The main focus will be on changes in vision and any side effects that may occur. The study will also involve the use of other medications, such as Omeprazole, which may be recommended for participants with certain risk factors, and Cefazolin Sodium, Vancomycin, and Cefuroxime, which are antibiotics used to prevent infections during eye surgeries. Additionally, Triamcinolone Acetonide, Dexamethasone Acetate, and Betamethasone are corticosteroids that may be used to reduce inflammation after surgery.

The purpose of this study is to gather information on how well the gene therapy works in improving vision and to monitor any potential side effects over time. Participants will be followed up regularly to check their vision and overall health. This study is part of a larger effort to find effective treatments for genetic eye conditions and to improve the quality of life for those affected by Retinitis Pigmentosa.

The purpose of the study is to explore the safety and effectiveness of this new treatment. Participants in the trial will receive a single dose of CPK850, and researchers will monitor them to see how well they tolerate the treatment and whether it helps improve their vision. The study will involve regular eye examinations and tests to assess changes in vision and eye health over time. These tests will include checking visual acuity, which is how clearly one can see, and examining the retina using imaging techniques.

Throughout the study, participants will be closely observed for any side effects or changes in their overall health. The trial aims to determine if CPK850 can help restore some of the lost vision in patients with this specific genetic form of Retinitis Pigmentosa. The study will continue for several years to gather comprehensive data on the long-term effects and benefits of the treatment.

The purpose of the study is to evaluate how effective and safe NAC is when taken twice a day over a period of 45 months. Participants will be randomly assigned to receive either the NAC treatment or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This approach helps ensure that the results are unbiased. Throughout the study, participants will have regular check-ups to monitor their vision and overall health.

Participants will undergo various assessments to measure changes in their vision, including tests that evaluate the sensitivity of the macula, which is the central part of the retina responsible for detailed vision. The study aims to determine if NAC can slow down the progression of vision loss compared to the placebo. By the end of the study, researchers hope to gather valuable information about the long-term safety and effectiveness of NAC for individuals with Retinitis Pigmentosa.